Table 3. Indicators of possible relevance to fluorescent tracers at a dose of 0.5 and 1 mg/kg.
| Characteristics | 0.5 mg/kg | 1 mg/kg | |||||
|---|---|---|---|---|---|---|---|
| Success (n=16) | Failure (n=2) | P value | Success (n=39) | Failure (n=12) | P value | ||
| Age (years) | 55.56±8.99 | 56.50±10.6 | 0.88 | 58.69±2.05 | 67.94±9.14 | 0.53 | |
| BMI (kg/m2) | 23.95±4.73 | 22.45±22.45 | 0.49 | 23.53±3.19 | 26.73±2.96 | 0.71 | |
| <24 | 10 (62.5) | 1 (50.0) | 25 (64.1) | 2 (16.7) | |||
| ≥24 | 6 (37.5) | 1 (50.0) | 14 (35.9) | 10 (83.3) | |||
| Tumor quadrant | 0.80 | 0.60 | |||||
| UOQ | 4 (25.0) | 0 (0.0) | 10 (25.6) | 2 (16.7) | |||
| OQT | 1 (6.3) | 0 (0.0) | 5 (12.8) | 3 (25.0) | |||
| LOQ | 3 (18.8) | 1 (50.0) | 7 (17.9) | 3 (25.0) | |||
| LQT | 0 (0.0) | 0 (0.0) | 4 (10.3) | 0 (0.0) | |||
| LIQ | 1 (6.3) | 0 (0.0) | 4 (10.3) | 0 (0.0) | |||
| IQT | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| UIT | 3 (18.8) | 0 (0.0) | 5 (12.8) | 3 (25.0) | |||
| UQT | 4 (25.0) | 1 (50.0) | 4 (10.3) | 1 (8.3) | |||
| Tumor grade* | 0.04 | 0.76 | |||||
| I | 3 (18.8) | 1 (50.0) | 7 (17.9) | 1 (8.3) | |||
| II | 10 (62.5) | 0 (0.0) | 18 (46.2) | 7 (58.3) | |||
| III | 1 (6.3) | 1 (50.0) | 11 (28.2) | 4 (33.3) | |||
| Histologic type | 0.04 | 0.61 | |||||
| IDC | 13 (81.3) | 1 (50.0) | 32 (82.1) | 10 (83.3) | |||
| ILC | 2 (12.5) | 0 (0.0) | 1 (2.6) | 0 (0.0) | |||
| CIS | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) | |||
| Other | 1 (6.3) | 1 (50.0) | 4 (10.3) | 2 (16.7) | |||
| T | 0.04 | 0.22 | |||||
| Tis | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) | |||
| T1 | 12 (75.0) | 2 (100.0) | 13 (33.3) | 8 (66.7) | |||
| T2 | 4 (25.0) | 0 (0.0) | 23 (59.0) | 4 (33.3) | |||
| T3 | 0 (0.0) | 0 (0.0) | 1 (2.6) | 0 (0.0) | |||
| N | 0.26 | 0.51 | |||||
| N0 | 14 (87.5) | 2 (100.0) | 29 (74.4) | 8 (66.7) | |||
| N1 | 2 (12.5) | 0 (0.0) | 7 (17.9) | 4 (33.3) | |||
| N2 | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) | |||
| N3 | 0 (0.0) | 0 (0.0) | 1 (2.6) | 0 (0.0) | |||
| Carcinoma in situ components | 0.87 | 0.26 | |||||
| Yes | 7 (43.8) | 1 (50.0) | 35 (90.0) | 10 (83.3) | |||
| No | 9 (56.3) | 1 (50.0) | 4 (10.3) | 2 (16.7) | |||
| Vascular invasion* | 0.12 | 0.55 | |||||
| Yes | 3 (18.8) | 0 (0.0) | 8 (20.5) | 2 (16.7) | |||
| No | 13 (81.3) | 2 (100.0) | 29 (74.4) | 10 (83.3) | |||
| Neural invasion* | – | 0.55 | |||||
| Yes | 0 (0.0) | 0 (0.0) | 6 (15.4) | 2 (16.7) | |||
| No | 16 (100.0) | 2 (100.0) | 31 (79.5) | 10 (83.3) | |||
| Molecular typing* | – | 0.002 | |||||
| HR+/HER2− | 13 (81.3) | 0 (0.0) | 26 (66.7) | 10 (83.3) | |||
| HR+/HER2+ | 2 (12.5) | 0 (0.0) | 3 (7.7) | 0 (0.0) | |||
| Basal-like | 1 (62.5) | 1 (50.0) | 6 (15.4) | 2 (16.7) | |||
| HR−/HER2+ | 0 (0.0) | 0 (0.0) | 2 (5.1) | 0 (0.0) | |||
Quantitative variables were described by mean ± standard deviation. Categorical variables were described as numbers and proportions. Group differences were compared using the ANOVA. Percentage totals may not add to 100% due to rounding. *, 2 cases of carcinoma in situ were not included in tumor grade, vascular invasion, neural invasion and molecular typing. One case of papillary carcinoma and 1 case of invasive carcinoma <0.1 cm were not included in tumor grade and molecular typing. One case of invasive carcinoma =0.1 cm was not included in tumor grade. BMI, body mass index; UOQ, upper outer quadrant; OQT, outer quadrant transition; LOQ, lower outer quadrant; LQT, lower quadrant transition; LIQ, lower inner quadrant; IQT, inner quadrant transition; UIT, upper inner transition; UQT, upper quadrant transition; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; CIS, carcinoma in situ; HR, hormone receptor; HER2, human epidermal growth factor 2; ANOVA, one-way analysis of variance.